Aiforia Prostate Cancer Suite

Aiforia® Prostate Cancer Suite is a clinical AI solution designed to support pathologists in prostate cancer diagnostics. Built around an optimized interactive user interface, the suite combines multiple AI models to assist with Gleason grade grouping, adverse histopathological feature identification, and comprehensive case-level reporting. It is intended for pathology labs seeking to enhance precision, speed, and diagnostic confidence through cutting-edge AI technology.

The suite delivers a fully digital cockpit for prostate cancer diagnostics, giving pathologists complete control over results. AI assistance is provided for first-read primary diagnostics, with automated suggestions for Gleason scoring, measurements, and the presence of adverse findings. The platform also enables time and cost savings through automated reporting and worklist prioritization.

AI Models Included in the Suite

• Aiforia® Prostate Cancer Biopsy: Automatically identifies adenocarcinoma and streamlines the Gleason grading process, directly addressing interobserver variability and small foci detection. Built on Aiforia's Foundation Engine technology, it delivers robust, high-performance results across real-world variation in sample quality, staining, and scanning. Clinical performance highlights include exceptional diagnostic accuracy with excellent correlation to expert grading, improved reproducibility, reduced interobserver variability, and analysis time savings of up to 68%. CE-IVD marked for diagnostic use in EU and EEA countries (IVDR); RUO and PSO in all other markets.
• Aiforia® Prostate Cancer PNI: Efficiently detects subtle perineural invasion (PNI) features, addressing the diagnostic challenge of accurately and consistently identifying tumor involvement around nerves. Highlights include high diagnostic confidence with excellent correlation to visual assessments, improved reproducibility for reliable PNI identification, and workflow efficiency improvements with scoring times reduced by up to 29%. CE-IVD marked for EU and EEA (IVDR); RUO and PSO elsewhere.
• Aiforia® Prostate Cancer G4 Cribriform: Automatically detects Gleason Grade 4 Cribriform patterns in prostate biopsy whole slide images (WSI), reducing diagnostic variability and enhancing workflow efficiency. Clinical highlights include excellent diagnostic reliability consistently aligned with expert visual assessments, improved reproducibility, reduced diagnostic variability, and analysis time reductions of up to 54%. CE-IVD marked for EU and EEA (IVDR); RUO and PSO elsewhere.
• Aiforia® Prostate Cancer HG-PIN: Supports the detection of high-grade prostatic intraepithelial neoplasia (HG-PIN) in whole slide images of prostate tissue. Currently available for Research Use Only (RUO) and Performance Studies Only (PSO) in all market areas.

Key Capabilities and Workflow Benefits

• Prostate-specific AI tools tailored to address the unique diagnostic challenges of prostate pathology, from detailed Gleason pattern recognition to adverse feature detection
• Precise, transparent results delivered through detailed visual overlays directly on digital slides, enabling easy visual confirmation at any magnification level
• Exact quantitative data including accurate tumor area measurements and cell counts, going beyond standard AI heatmaps
• Comprehensive case-level review and reporting that combines results from multiple AI models, WSIs, and stainings into a single unified view
• AI results populated directly into the reporting panel, with advanced features such as case list triaging, pre-ordering of extra stains, and flagging of non-representative samples
• Support for pathologist correction of AI analysis with immediate implementation of corrections into results, enhancing accuracy and consistency

Why Aiforia® Clinical Suites for Prostate Cancer

• Enhances consistency and clarity in interpretation across a range of prostate cancer cases
• Empowers pathologists with both visual transparency and actionable quantitative insights
• Speeds up each step in the diagnostic workflow, from initial analysis to final reporting
• Reduces repetitive tasks while improving accuracy and consistency of image analyses

Certain Aiforia® Clinical AI models and the Aiforia® Clinical Suite Viewer are CE-IVD marked for diagnostic use in EU and EEA countries under IVDR, while other models are available for Research Use Only (RUO) or Performance Studies Only (PSO) in markets outside the EU and EEA. The suite is compatible with a range of whole slide image scanners and is designed to integrate into existing digital pathology workflows.